Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancerPeter Bankhead, Peter W. Hamilton, Manuel Salto‐Tellez et al.|Laboratory Investigation|2017Cited by 122
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancerDavid P. Boyle, Manuel Salto‐Tellez, Darragh G. McArt et al.|Histopathology|2014Cited by 67
Automated tumor analysis for molecular profiling in lung cancerPeter W. Hamilton, Manuel Salto‐Tellez, Yinhai Wang et al.|Oncotarget|2015Cited by 59
Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatmentNiamh E. Buckley, Manuel Salto‐Tellez, Darragh G. McArt et al.|Scientific Reports|2016Cited by 50
PICan: An integromics framework for dynamic cancer biomarker discoveryDarragh G. McArt, Peter W. Hamilton, Jaine K. Blayney et al.|Molecular Oncology|2015Cited by 14